Introduction
Muscle atrophy is associated with severe human pathologies, such as degenerative diseases and cancer (von Haehling et al., 2010) . For example, Amyotrophic Lateral Sclerosis (ALS) is characterized by the death of motorneurons and the atrophy of skeletal muscles, which leads to paralysis and death due to a lack of an efficient cure (Ludolph et al., 2012) . During cancer, muscle atrophy may develop as a side effect of the chemotherapy (cisplatin, doxorubicin) (Garcia et al., 2013; Gilliam and St Clair, 2011; Hydock et al., 2011) , or at the late stage of the pathology (Fearon et al., 2012) .
This muscle-wasting syndrome (or cachexia) drastically reduces the patient's quality of life and may force the clinician to stop the treatment. The lack of an efficient cure against muscle atrophy correlates with a poor knowledge of the mechanisms involved.
Although the origin of muscle atrophy differs between pathologies, common features can be identified that play an important role in fiber and myoblast alterations, such as an abnormal production of ROS (Barbieri and Sestili, 2012; Gilliam and St Clair, 2011; Ray et al., 2012) . In particular, elevated ROS production has been linked to the presence of mutations in the ROS detoxification enzyme SOD1 associated with hereditary ALS (Beckman et al., 2001) . Similarly, cisplatin and doxorubicin have been shown to induce the production of ROS (Chirino and Pedraza-Chaverri, 2009 ) (Garcia et al., 2013; Gilliam and St Clair, 2011; Hydock et al., 2011 ) (Gilliam et al., 2013 . ROS production has also been linked to the muscular atrophy induced by the presence of a tumor, likely mediated by cytokines such as TNF-alpha (Adams et al., 2008) . At the cellular level, production of ROS induces lipid peroxidation, protein oxidation, DNA damage, and mitochondrial dis-functions. These cellular alterations activate specific signaling pathways such as the unfolded protein response (UPR) and/or transcription factors such as p53/p73, which in turn lead to cell death and tissue degeneration (Barbieri and Sestili, 2012; Benosman et al., 2007; Benosman et al., 2011; Gonzalez de Aguilar et al., 2000) .
In order to counteract the atrophy process, small molecules have been tested for their cytoprotective properties. Two examples of these drugs are tocopherol and flavonoid derivatives. Flavonoid derivatives can reduce ROS effects and present neuroprotective or cardioprotective activity (Hauss et al., 2007; Ribeiro et al., 2012; Thuaud et al., 2011) . Several molecules that act on regeneration and neuroprotection are derived from tocopherol, a member of the vitamin E family, which is widely used in clinical practice because of its antioxidant and anti-inflammatory properties (Singh and Jialal, 2004) . Moreover, alpha-tocopherol derivatives are considered disease modulators in multiple sclerosis (MS) and show beneficial outcomes after white matter damage in experimental models (Blanchard et al., 2013) (Coowar et al., 2004) .
The notch pathway is an intercellular developmental signaling cascade with fundamental roles in muscles (Bjornson et al., 2012) (Buas and Kadesch, 2010) ( Guruharsha et al., 2012) . This pathway comprises four receptors (Notch 1-4) and several ligands (Delta-like, Jagged) that mediate their biological function through induction of target genes like Hes1 and HeyL (Bjornson et al., 2012) (Buas and Kadesch, 2010) . Several studies showed that Notch signaling favors myoblast proliferation, and when sufficient myoblast are produced, Notch signaling needs to be switched off again to allow myoblast differentiation (Buas and Kadesch, 2010) . This sequential regulation of the Notch pathway plays a central role in muscle development and muscle regeneration. For example, Notch3 silencing leads to muscle hypertrophy due to excess regenerative processes (Kitamoto and Hanaoka, 2010) . Inversely, the expression of a general dominant negative Notch peptide leads to severe muscle defects showing similarities with muscular dystrophy (Lin et al., 2013) . These apparently contradictive results suggest that individual Notch components have a timely and cell specific function in muscle development and repair that still remains to be defined more precisely.
In view of the cytoprotective effects of tocopherol and flavonoid derivatives, we decided to investigate the ability of novel derivatives presenting an omega-alkanol chain to improve the health of animals that are affected by muscle atrophy. We chose the omega-alkanol part, a fatty alcohol chain, as it was previously shown to provide cytoprotective properties on neurons (Borg et al., 1987) (Azzouz et al., 1996) (Hauss et al., 2007) . We therefore hypothesized that the hybrids would combine the antioxidant properties of the tocopherol and the activity of the fatty alcohol chain, providing interesting cytoprotective activity on muscles. In addition, based on the role of the Notch pathway in muscle regeneration we tested whether these hybrid compounds might regulate this pathway during the pathology associated with muscular atrophy.
Methods

Chemicals and Synthesis
AGT048, AGT251 and AGT262 tocopherol derivatives synthesis were performed as described previously (Muller et al., 2006) . AGT072 hydroquinone synthesis was also described previously (Coowar et al., 2010) . AGT031, AGT171, AGT184 and AGT216 flavonoid derivatives were synthesized following the chemical scheme described in patent (Coowar et al., 2009) .
Cell cultures
Murine C2C12 myoblasts were obtained from ATCC. C2C12 cells were manipulated and cultured in DMEM with 10% FCS (Dominique Dutcher TM ) and 1% Penicillin + Streptomycin (Sigma) at 37°C with 5% CO 2 atmosphere as previously described (Sohm et al., 1999) .
Cell survival
2000 cells were seeded per well in 96-well microplates (Falcon Multiwell), 48 h prior to any treatment. Cisplatin and menadione (Sigma) were applied for 48 h in fresh medium. MTT assay was performed as previously described by replacing the medium with fresh medium supplemented with 5 mg/L MTT (Sigma) for 1h (Gaiddon et al., 1999) . Cells were lysed in isopropanol with 0.04 N HCl. Measurements were performed at 550 nm.
Quantitative PCR.
Cultured cells were lysed with 1ml of TRIzol per 10 cm². Mice were sacrificed by cervical dislocation, hindlimb gastrocnemius muscles were sampled, immediately frozen in liquid nitrogen and stored at -80°C for later use. 1 ml TRIzol (Invitrogen) per 150 mg of muscle was used to extract RNA according to manufacturer's instructions. RNA samples were ethanol-precipitated twice and 1 µg was used for reverse transcription (High-Capacity cDNA Reverse Transcription Kit, Applied Biosystems). qPCR was performed using 2 ng/µl cDNA (RNA equivalent) according to manufacturer's instructions (SYBR Green PCR Master Mix, Applied Biosystems) and with 400 µM of each primer (Supplemental data, table 1). Expression levels were normalized using average of 18S.
SOD1* mice
SOD1* mice are FVB transgenic mice expressing the missense mutation G86R (human G85R equivalent) in the SOD1 gene (Ripps et al., 1995) . Transgene expression was monitored by PCR on SOD1 (F: GACATCATTGTTCATCC R: ATTGATGGAATGCTCTCCTGA), FspI digestion and agarose electrophoresis (Ripps et al., 1995) . We distinguished several experimental groups based on age and the presence of symptoms: asymptomatic 60 days-old mice, asymptomatic 75 daysold mice, early symptomatic mice (90 days; presenting sign of denervation as indicated by up-regulation of the mRNA for Acetylcholine receptor alpha subunit) and symptomatic mice (105-110 days) when full paralysis in on.
Mice treatment
SOD1* mice were injected intraperitoneally 3x/week beginning at an age of 65 days (Rene et al., 1996) . AGT251 (20 mg/Kg) was administered in 0.9% NaCl with 6% 1 1
Results
Tocopherol and flavonoid derivatives impact on myoblastic cell survival
The effect on cell survival of several flavonoid or tocopherol derivatives (AGT) was assayed on C2C12 cells, a commonly used in vitro model for myoblast cells. Doseresponse survival relationships were established by means of an MTT assay and using a large window of concentrations (1nM-125µM) (Fig. 1A) . Most compounds were reducing survival with an IC 50 between 50 and 125 µM, although 3 compounds were already active at lower concentrations (Fig. 1A , Table 1 ). The toxic effect of these compounds at high concentrations correlated with the up-regulation of p21 and noxa expression (Fig. 1B) . p21 and noxa were chosen as they represent markers for cell growth arrest and apoptosis, respectively (Benosman et al., 2011) . Interestingly, two compounds significantly increased cell survival by 22% (AGT048 25 µM) or 41% (AGT251 15 µM) at concentrations preceding toxicity. AGT031 did not show any pro-survival effect and was more toxic than most compounds. Thus, it was used as a control in subsequent experiments.
AGT048 & AGT251 protect against oxidative and DNA damage induced stresses
As AGT048 and AGT251 compounds were increasing cell survival, we assessed whether these compounds could also improve viability upon stresses associated with degenerative syndromes. Therefore, C2C12 were treated with: i) menadione that induces a strong production of anion superoxide (Rosen and Freeman, 1984) and ii)
cisplatin that induces DNA damage and mild ROS production (sup data #1A) (Vidimar et al., 2012) . We observed that AGT048 and even more AGT251 were able to increase cell survival in presence of cisplatin and to a lesser extent of menadione 1 2
( Fig. 2A-B) . Under the same condition AGT251 reduced ROS production induced by cisplatin and menadione (sup data #1B). As expected, AGT031 did not increase cell survival.
To further assess the pro-survival activity of AGT251 at the molecular level, we analyzed the expression of p21 and noxa. We observed that in C2C12, cisplatin induced p21 and noxa expression (Fig. 2C) . At the dose of AGT251 that favored survival (10 µM), the cisplatin-induced expression of p21 was unchanged, while the expression of the pro-apoptotic gene noxa was decreased. Taken together, these experiments demonstrated that AGT251 protects myoblast cells against DNA damaging stress in vitro.
AGT251 modulates the notch pathway
To further understand the biological properties of the AGT251 tocopherol derivative, we then focused on the Notch pathway for two reasons. First, previous work has shown that compounds sharing a similar structure to our compounds were able to repress Notch4 RNA expression in neurospheres correlating with an increased neuronal survival (Blanchard et al., 2013 ) (Coowar et al., 2004 . Second, it has been shown that the notch pathway is playing a key role in muscle regeneration and myoblast survival (Bjornson et al., 2012) (Buas and Kadesch, 2010) and is regulated by the physiological status of the mitochondria (Arthur and Cooley, 2012; Kasahara et al., 2013) .
Before evaluating the effect of AGT251 on the Notch pathway in stressed myoblastic cells, we first characterized the impact of cisplatin on the expression of Notch receptors (Notch 1-4) using RT-qPCR (Fig. 3A) . A cytotoxic dose of cisplatin (7.5 µM) induced an upregulation of Notch1, Notch3 and Notch4 mRNA levels. It is to 1 3 note that the expression level of Notch4 in C2C12 cells was low (Ct ± 30). To assess the functionality of these regulations, we also evaluated the expression of Notch target genes and observed an increase of Hes1 and HeyL mRNA upon cisplatin treatment.
We then tested how AGT251 might affect the cisplatin-induced activation of the Notch pathway. We found that pro-survival doses of AGT251 (Fig. 1A, 3B ) caused a decrease of cisplatin-induced expression of Notch1 and Notch3 expression, while Notch4 was further induced (Fig. 3C) . Importantly, the repression of Notch1 and Notch3 correlated with a diminished expression of Notch target genes, such as Hes1.
Taken together, these results indicated that the Notch pathway was induced by a cytotoxic dose of cisplatin, and that this induction was reduced by AGT251. In particular, we observed a correlation between the expression of Notch1, Notch 3 and Hes1 upon treatment with AGT251.
AGT251 protects muscles from doxorubicin-induced cachexia
To assess whether our observation made on C2C12 cells in vitro were physiologically relevant, we decided to use a murine model for cachexia. Cachexia is a severe syndrome including muscle atrophy observed in cancer patients with certain cancer localizations (such as pancreatic cancer) and in patients treated with doxorubicin (Fearon et al., 2012 , 2010) . These studies show evidences that muscle fibers as well as the progenitor pool seem to be affected and that the induction of ROS is a proposed cause of doxorubicin-induced myopathy.
To assess the effect of AGT251 on atrophy, two groups of mice were both treated once with doxorubicin (18 mg/kg) to induce cachexia and one of them was also treated three times a week with AGT251 (20 mg/kg). The AGT251 dose was established as the maximal dose tolerated by the mice without noticeable adverse effect based on the body weight and behavior. After 15 days of treatment, total mouse weight and skeletal muscle weight were measured and RNA was extracted from muscles to quantify the expression of muscle atrophy markers (MuRF1 and Atrogin-1). We observed a loss of total animal and muscle weight upon doxorubicin treatment (Fig. 4A , B) confirming its atrophic effect on the muscle. This effect correlated with an up-regulation of the two effectors and markers for muscle atrophy, MuRF1 and Atrogin-1 (Fig. 4C ). Very interestingly, we observed that the co-treatment with AGT251 partially reversed the muscle atrophy as assessed by muscle weight (Fig.   4A ). This effect was further confirmed by the repression of MuRF1 and Atrogin-1 expression upon AGT251 treatment (Fig. 4C ). Based on our results, AGT251 appeared to protect muscles against atrophy under conditions inducing cachexia.
To investigate the impact of muscle atrophy and AGT251 on the Notch signaling pathway in vivo, we measured the expression of Notch receptors and Notch target genes. Upon doxorubicin treatment, expression of Notch1 and Notch3 was induced (Fig. 4D) . Expression of the Notch target gene Hes1 was also increased by promoter and a reporter gene containing the promoter of the Notch target gene Hes1.
As expected, overexpression of the intracellular domain of Notch3 (NICD), alone or with its co-activator CBF, led to an increase in the Hes1 promoter activity (Fig. 4F) .
Interestingly, NICD also stimulated the activity of the MuRF1 promoter.
Altogether these results confirmed that the activity of the Notch pathway is induced upon muscle injury, such as the one generated by doxorubicin, and that AGT251 is able to partly counteract this effect.
AGT251 increases survival in a murine model of ALS
Given its protective effect on myoblasts in vitro, and the protection against doxorubicin-induced muscular atrophy, we wondered if treatment with AGT251 could be beneficial for mice showing a progressive degeneration of the muscle that leads to death. In addition, by using another model we wanted to assess whether AGT251 might have a broad protective effect independently of the etiology of the disease.
Thus, we next studied mice with a substitution mutation in the Cu/Zn Superoxide Dismutase 1 gene (SOD1*) that are used as a model of the human pathology Amyotrophic Lateral Sclerosis (ALS) (Gonzalez de Aguilar et al., 2000; Ripps et al., 1995) . Although the G86R mutation in the SOD1 (SOD1*) does not affect the SOD1 activity, the mice carrying the SOD1* transgene develop an oxidative stress (Gonzalez de Aguilar et al., 2000; Ripps et al., 1995) . In average, SOD1* mice die at , 2000; Ripps et al., 1995) . The denervation of the animal can be followed by the expression of the acetylcholine alpha-receptor gene in the muscles (Fig. 5A ). In addition, the level of muscular atrophy can be assessed using markers such as the MuRF1 and Atrogin-1 genes (Foletta et al., 2011) (Fig. 5B ).
We first assessed whether in this model the expression of components of the Notch pathway were altered in the muscles during the ALS pathology ( Fig We used then this mouse model to assess whether AGT251 could prolong life span.
We treated SOD1* mice thrice a week with AGT251 (20 mg/kg) starting at an asymptomatic age of 65 days. Treatments were performed until death. The efficacy of
Discussion
Muscular atrophy is occurring in several lethal human diseases such as neuromuscular syndromes, like ALS or cancer. In cancer, it has been estimated that about 30% of the mortality of cancer is due to cachexia that includes muscle atrophy. In the case of ALS, respiratory muscle atrophy is also the cause of death. This dramatic clinical status is a direct reflection of the absence of a curative treatment for muscle atrophy. In this study, we investigated the beneficial effect of flavonoid and tocopherol derivatives on skeletal muscles based on their anti-oxidant and antiinflammatory properties that have previously shown protective activity on the nervous system and the heart. In addition, we investigated some of the molecular mechanisms potentially involved in the muscle protection by focusing on the Notch pathway.
Cellular effects of novel flavonoid and tocopherol derivatives
The synthesized flavonoid and tocopherol derivatives and hybrids with an omegaalkanol chain showed in vitro biological activity on the C2C12 myoblast cell line.
Above a specific concentration, each compound reduced cell survival as observed by MTT tests and by the induction of cell growth arrest and pro-apoptotic genes p21 and noxa (Table 1 , Fig. 1 ). However, a moderate concentration of two tocopherol derivatives, AGT048 and AGT251, sharing a similar pharmacophore, stimulated survival. Importantly, at these sub-toxic concentrations AGT048 and AGT251 partly counteracted the toxic effect of cisplatin or menadione on C2C12 cells (Fig. 2 ), which correlated with a reduced level of the pro-apoptotic gene noxa (Fig. 2C ). In addition, AGT251 restored the expression level of two myoblastic cell markers, Pax7 and
MyoD, that were both downregulated by cisplatin (supplementary data #4). All the tested flavonoid and tocopherol derivatives share all the same omega-alkanol chain.
However, only two tocopherol derivatives present the protective effect on C2C12 cells, which suggests that the this effect is not mediated by the omega-alkanol chain but more likely by an intact tocopherol core. This is further supported by the fact that the protective effect of AGT251 correlates with the reduction of ROS production in C2C12 cells (supplementary data #1B).
Tocopherol derivatives diminish the stress-induced expression levels of Notch1,
Notch3 and Hes1 in muscles
A recent study showed that the Notch pathway is involved in muscle repair during ageing or physical damage (Arthur and Cooley, 2012) . In addition, it was previously shown that tocopherol derivatives repressed mRNA level for Notch4 in neuronal cells (Coowar et al., 2004) . Our study brings novel information on these two aspects.
Concerning the first aspect, we uncovered the first evidence of a regulation of the Notch pathway during ALS or cachexia. Indeed, we observed both in vitro (C2C12 myoblatic cells) and in vivo (murine models of ALS and doxorubicin-induced cachexia) an induction of the Notch pathway upon various stress. In particular, we showed a correlation between the upregulation of Notch1 and Notch3 expressions and their target gene Hes1. Based on the complex nature of the muscle that includes fibers, muscle progenitors, vessels and neuromuscular junctions for example, it is difficult to definitively conclude that the regulation of Notch observed in vivo is solely due to muscle cells. We can only hypothesize that part of these regulations are indeed involving muscle cells based on our results in C2C12 and the literature indicating that the Notch pathway is regulated in myoblastic cells and participate in the control of muscle development and regeneration. It also remains to establish the
2 0 consequences of these regulations in the muscles and more specifically in the progenitors and the fibers. As indicated by the literature, the Notch pathway seems to play a role in maintaining muscle stem cell quiescence (Bjornson et al., 2012) ( Mourikis et al., 2012) . Therefore, the increase of Hes1 expression during the pathologies, or after in vitro treatment with anticancer drugs, might contribute to muscle atrophy by maintaining at least a subpopulation in a quiescent state. The exact and respective contribution of Notch1 and Notch3 in this process needs to be more clearly established. In addition, our observation that NICD regulates the promoter of the atrophic/remodeling factor MuRF-1 might suggest that the Notch pathway could play a role in fibers. We also observed some differences in the response between the models. For example, we found in vitro an induction of HeyL expression that we did not see in vivo. This is surprising since two recent publications indicated that HeyL might play a more important role than Hes1 in the maintenance of satellite cell number in the muscles (Buas and Kadesch, 2010) (Fukada et al., 2011) . In contrast to this, our results might indicate that in the injury/repair processes, for instance taking place in response to doxorubicin and in ALS-related syndrome, it is the opposite with Hes1 being more important than HeyL. However, the exact role of Notch1, Notch3
and Hes1 in the atrophic process and whether it is related to the regulation of the differentiation and proliferation equilibrium of satellite cells or fiber atrophy remain to be established. Interestingly, our study also suggested that Notch might be involved in muscle atrophy via an induction of the atrophic/remodeling effector MuRF1, which provides a novel possible avenue in the overall function of the Notch pathway in muscle development and repair.
Concerning the second aspect, our data confirmed that tocopherol derivatives, such as AGT251, affect the activity of the Notch pathway. Indeed, AGT251 treatment partly This article has not been copyedited and formatted. The final version may differ from this version. counteracted both in vitro and in vivo the stress-induced Notch pathway activation.
However, in C2C12 myoblastic cells and in muscles of ALS or doxorubicin treated animals, the repression was mostly observed on Notch1 and Notch3, but not on Notch4 as previously seen in neurons (Coowar et al., 2004) . In addition, here we also provided the first evidence that the regulation of the Notch receptor by the tocopherol derivatives impacts on Notch target genes.
It remains to be precisely understood how AGT251 might act on the Notch pathway.
As indicated above, one possibility is that due to its antioxidant properties, AGT251
protects the cells against the oxidative stress induced by cisplatin, doxorubicin or mutant SOD1 (supplementary data #1B), hence reducing the induction of Notch. This suggests that AGT251 might help to restore the properties of the myoblastic cells. This is partly supported by the fact that AGT251 reduces the inhibition of Pax7 and
MyoD expression caused by cisplatin in C2C12 cells (Supplementary data #4).
Alternatively, the antioxidant properties of AGT251 might also protect the fibers from atrophy. In addition, one recent interesting observation is that the Notch pathway is a relay towards myocyte differentiation induced by variations in the mitochondria physiological activity (Kasahara et al., 2013) . Therefore, based on the anti-oxidant activity of the tocopherol derivative (supplementary data #1B), one hypothesis might be that by controlling the mitochondrial redox status, AGT251 might regulate the Notch pathway. In addition, a more recent study indicates that the Notch pathway is partly controlled partly by Nrf2, which is a Redox sensitive factor (Paul et al., 2014) .
Therefore, one hypothesis might be that the regulation of the Notch pathway by the antioxidant AGT251 or during ROS-related muscle atrophy could involve Nrf2.
This article has not been copyedited and formatted. The final version may differ from this version. 
A tocopherol derivative ameliorates mouse survival in ALS model and reduces muscle cachexia
The in vitro trophic effect of tocopherol derivatives on myoblast cell line survival observed in vitro was validated using in vivo murine models. Indeed, sustained injection of AGT251 in a model of cachexia (doxorubicin-treated mice) ameliorated mice health, both on the overall weight of the mice and more specifically on the muscular weight, going along with the down-regulation of effectors and markers of muscular atrophy (MuRF1 and Atrogin-1). The protective effect of the tocopherol derivative AGT251 on muscles was further confirmed as AGT251 prolonged slightly but significantly survival of mice developing ALS with severe muscle atrophy. Of note the observed benefice is close to what has been previously observed for Riluzol in mice, the only FDA-approved treatment for ALS (Gurney et al., 1996) . This effect might be linked to an improved resistance of muscle fibers and/or motoneurons that are both primary tissues affected by the pathology. More generally, the pro-atrophic effect of doxorubicin and mutated SOD1, as well as the protective effect of AGT251, might involve several components of the muscle that ultimately lead to an improvement or alteration of muscle and fiber size, respectively. For example, it is likely that the changes in the levels of reactive oxygen species caused by doxorubicin, mutant SOD1 and AGT251 in the fibers and the progenitors might impact on muscle atrophy.
Altogether, our in vitro and in vivo data indicate that specific tocopherol derivatives can improve syndromes that involve skeletal muscle atrophy, such as observed in ALS or cancer-related cachexia. It also points out that the notch pathway is regulated during muscle atrophy with specificities depending on the pathology, and our data suggest that Notch1, Notch3 and Hes1 seem to be potential players in these processes.
This article has not been copyedited and formatted. The final version may differ from this version. However, it remains to more precisely establish the exact contribution of Notch1, Notch3 and Hes1 in the atrophic and regenerative processes. Consequently, designing molecules that target the notch pathways might be an interesting avenue to develop drugs aiming at the protection of muscle against various stresses.
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: This article has not been copyedited and formatted. The final version may differ from this version. were assayed in C2C12 myoblast cells treated with cisplatin (7.5 µM) for 24 hours using RT-qPCR. Graphs are means of fold induction versus Ct with SD (n=3). *: p< 0.01 as calculated by a one-way ANOVA test followed by a Tukey post-test. B.
Figure legends
C2C12 myoblast cells were cultured for 48 hours in presence of cisplatin (7.5 µM) in absence or in presence of AGT251 (in µM). Cell survival was evaluated using MTT test. Curves indicate mean ± SD (n=8) relative to control in absence of cisplatin. *: p< 0.01 compared to control, as calculated by a one-way ANOVA test followed by a Tukey post-test. C. mRNA levels of components of the notch signaling pathway were assayed in C2C12 myoblast cells treated for 24 hours with cisplatin (7.5 µM) in absence or in presence of AGT251 (in µM) using RT-qPCR. Graphs are means of fold induction versus Ct with SD (n=3). *: p< 0.01 as calculated by a one-way ANOVA test followed by a Tukey post-test. 
